Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

NEW YORK and LONDON, December 19 /PRNewswire/ --

- Strategic Partnership Expands Linkstorm's Reach in European Market

Advertising technology company Linkstorm is ramping up its sales effort in the European online advertising business thanks to a new partnership with GMW Media, Ltd., a United Kingdom-based independent online media sales house.

GMW Media was founded in 2005 by Mark Wright, a veteran in online sales who has worked for companies such as Rivals.net, Sports.com, Teamtalk Media and Sportinglife. The company offers Linkstorm an extended sales team with local market know-how and contacts, thus raising Linkstorm's visibility with GMW's fast-growing network of advertisers and publishers.

PHILADELPHIA and LONDON, December 19 /PRNewswire/ --

- Award Winners were Chosen for Leading Innovation Through Technology in all Aspects of Scientific Literature and Patent Publications

Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced the winners of the 2007 Innovation Award, recognizing leadership in technology as it relates to all aspects of scientific literature and patent publications in India.

ALZENAU, Germany and CHERNOBYL, Ukraine, December 19 /PRNewswire/ -- NUKEM Technologies GmbH, Alzenau has handed over the Engineered Near Surface Disposal Facility at Chernobyl to the customer SSE Technocenter on 19 December 2007. By doing so, NUKEM as the first Western company, has successfully completed a plant for the treatment of radioactive waste on location Chernobyl up to the handover to the customer.

In the Engineered Near Surface Disposal Facility, short-life radioactive wastes accumulated in the nuclear power plant Chernobyl are stored following prior conditioning. The repository is situated 17 kilometres away from the power plant at the location VEKTOR within the 30-km zone.

SANTA CLARA, California, December 19 /PRNewswire/ --

- Marvell PXA 300 Application Processor Delivers Both Outstanding Multimedia and Optimal Business Applications Functionality

Marvell, (Nasdaq: MRVL), a leader in storage, communications, and consumer silicon solutions, and Samsung, announced the availability of the Samsung SPH-M4650 PDA phone with the Marvell(R) PXA 300 application processor running on Korea's LG Telecom network. The Marvell PXA 300 application processor enables high-end graphics, gaming, and multimedia capabilities for the Samsung SPH-M4650 as well as delivering optimal business applications while consuming ultra-low levels of power. The Samsung SPH-M4650 runs on the Microsoft Windows Mobile 6.0 Professional operating system.

AMSTERDAM, December 19 /PRNewswire/ --

- FDA Offers Special Protocol Assessment for Reviroc

Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.